【佳学基因检测】癌基因及其产物在人类癌症中的诊断效用

基因检测价格表国产

在高峰论坛中肿瘤基因检测及基因突变的改进与提高获悉《Biochim Biophys Acta》在. 1991 Dec 10;1072(2-3):193-214.发表了一篇题目为《癌基因及其产物在人类癌症中的诊断效用》肿瘤靶向药物治疗基因检测临床研究文章。该研究由S J McKenzie等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

致癌基因与特定癌症的第一个明确关联是慢性粒细胞性白血病和急性淋巴细胞性白血病中的 c-abl 易位。在 90% 的 CML 检查病例中观察到了这种情况。这是其成为 FDA 批准的第一个基于致癌基因的诊断测试目标的主要因素。尽管 abl 易位在致瘤过程中的作用尚不清楚，但很明显它一定与疾病有因果关系，因此是诊断测试的理想目标。这种癌基因与特定癌症的关联是未来所有其他癌症基因的模型。第二代测试可以很容易地包括对 mRNA 的 PCR 和/或原位杂交，这两者都可以使用血液样本进行。这两种基因解码基因检测的研究方法都将提供一种更快的基因解码基因检测的研究方法来测试大量细胞，但是，必须分别通过自动化和计算机辅助图像分析来改进基因解码基因检测的研究方法，才能成为有用的常规测试。 neu 和表皮生长因子受体 (EGFR) 似乎在基因产物的过表达与乳腺癌疾病基因解码基因检测的研究结果之间具有密切的相关性。为疾病预后提供有价值的信息。再一次，虽然这些分子的实际作用机制以及它与致瘤过程的关系尚不清楚，但从分子的本质来看，人们认为它们必须以某种方式促进疾病的进展。在这两种情况下，蛋白质产物在组织中都过表达，在 Neu 的情况下，似乎至少有一些患者的血清中有 Neu 相关蛋白。这些分子为诊断/预后分析的开发提供了相对容易的目标，因为抗体很容易制造并且可以整合到各种分析形式中。目前可用的检测基因解码基因检测的研究方法，即用于 Neu 的 ELISA 和用于 EGFR 的放射性配体结合检测，具有高灵敏度、可重复性和相对容易执行的特点。然而，只有 ELISA 是市售的，因此可以轻松地在实验室之间进行比较。然后，朝着常规测量 EGFR 迈出的一个明显的步骤是开发可比较的商用测试。两种检测基因解码基因检测的研究方法的改进是结合内部对照来测量被测组织样本的细胞成分。将 myc 和 ras 应用于癌症诊断的基因解码基因检测的研究结果并不那么容易预测，但有几个例外。（摘要截断为 400 字）

肿瘤发生与复发转移国际数据库描述：

The first clear cut association of an oncogene with a specific cancer is the c-abl translocation in chronic myelogenous leukemia and acute lymphocytic leukemia; it has been observed in 90% of CML cases examined. This is the major contributing factor to its being the target of the first oncogene-based FDA-approved diagnostic test. Although the role of the abl translocation in the tumorigenic process is not yet understood, it is clear that somehow it must be causally related to the disease, and thus is an ideal target for a diagnostic test. The association of this oncogene with a specific cancer is the model on which all others may be based in the future. Second generation tests could easily include PCR on mRNA, and/or in situ hybridization, both of which could be performed using blood samples. Both methods would provide a faster means of testing a large number of cells, however, the methodologies must be improved through automation and computer-aided image analysis, respectively, in order to become useful routine tests. Both neu and epidermal growth factor receptor (EGFR) appear to have a close correlation between overexpression of the gene product and outcome of disease in breast cancer; valuable information for prognosis of the disease. And again, although the actual mechanism of action of these molecules and how this relates to the tumorigenic process is not yet known, it is believed from the very nature of the molecules that they must in some way contribute to the progression of the disease. In both cases, the protein products are overexpressed in tissue, and in the case of Neu, it appears as through at least some of the patients have a Neu-related protein in their serum. These molecules present relatively easy targets for the development of diagnostic/prognostic assays, as antibodies are easily made and can be incorporated into a variety of assay formats. Current assays available, an ELISA for Neu and a radio-ligand binding assay for EGFR, are highly sensitive, reproducible and relatively easy to perform. Only the ELISA is commercially available, however, and hence allows for easy comparison between laboratories. An abvious step towards the routine measurement of EGFR then is the development of a comparable commercially available test. An improvement for both types of assay would be the incorporation of an internal control to gauge the cellular component of the tissue samples that are tested. The outcome of the applications of myc and ras to cancer diagnostics is not so easily predictable, with a couple of exceptions.(ABSTRACT TRUNCATED AT 400 WORDS)

• 上一篇：【佳学基因检测】前庭神经鞘瘤的放射生物学：放射抗性机制和治疗致敏的潜在靶点
• 下一篇：【佳学基因检测】结节性硬化症和癫痫：近期发展和未来挑战

• 收藏
• 挑错
• 推荐
• 打印